Red birthmark new drugs will be listed in China's pharmaceutical companies to promote drug innovation
December 07, 2016 Source: China Pharmaceutical Network
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Â Port wine stains, commonly known as red birthmarks, are congenital superficial skin vascular malformations with an incidence of 0.3% to 0.5%, mostly occurring on the face and neck. Currently, there are already treatments in the market. According to Zhang Jiang, the world's first drug for the port wine stains, Fumeta, will be officially launched in the middle of this month. However, it does not give the specific market share that it is expected to achieve.
It is understood that by then, Sinopharm will be the general distributor of the former. According to the data given by Fudan Zhangjiang, in the past few decades, the stock of fresh spotted scutellaria has reached nearly one million people, and the annual treatment demand exceeds 1 billion yuan. The total market demand in the next decade will reach 20 billion. However, it does not give the specific market share that it is expected to achieve.
It is worth mentioning that on May 30 last year, Fudan Zhang Jiang issued an announcement stating that it intends to apply for return to A shares. On the same day, in response to the current situation, it said that the corresponding work is still in progress, and "do not rule out finding other ways to get through this path."
Lock the "niche market"
According to the reporter, laser treatment of red birthmarks, especially pulsed dye laser treatment of red birthmarks is safe and effective for most patients, especially younger patients. However, Tu Ping, a professor at Peking University First Hospital, pointed out that the technique is only effective for some patients because of its requirements for the thickness of the diseased blood vessels.
Although this market is relatively small, the data given by Fudan Zhangjiang believes that the market size is not small, with a neonatal rate of 0.3% to 0.5%, and 10 million newborns per year in China. Up to 30,000 to 50,000 people, the demand for treatment of red birthmarks may reach 1 billion yuan, plus the stock of patients in the past few decades, Fudan Zhangjiang believes that the total market demand in the next decade is as high as 20 billion yuan. According to industry insiders, based on this, in the context that the effects of traditional treatment methods are far from effective, the opportunities for new entrants are not small.
According to the information provided by Fudan Zhangjiang, as early as 2001, the company decided to declare in the field of treatment of port wine stains. It has been 16 years now. Prior to October 2016, it had obtained production approvals.
Su Yong, deputy general manager of Fudan Zhangjiang, said on December 3 that at present, although Fumeida will be officially listed, it will carry out four phases of clinical follow-up. “We need to be more optimistic about the safety and effectiveness of this drug. Even how its effectiveness is further improved, how the patient feels further improvement. In addition, Su Yong also said that it will launch clinical trials for children under 14 years of age. However, Fudan Zhang Jiang did not give specific data in response to the reporter's question about the expected market sales scale in the future.
Shi Lichen, the head of Beijing Dingchen Medical Management Consulting Center, told reporters that the current hot spot for innovative drugs is a major disease, compared with the market for port wine stains, and there are not many corresponding drugs. Even so, after the launch of this innovative drug from Fudan Zhangjiang, it is difficult to predict how big the sales scale will be. “How many consumers have access to this drug after the product comes out? How many consumers can afford it? All need to be considered. And this kind of disease has not been treated before.†In his view, due to market size restrictions, There are not many pharmaceutical companies that are innovating in similar niche markets. However, according to the general rule, the number of patients who use Fumeida products in the future can account for a tenth of the overall.
The industry also said that in the context of consumers prefer to import drugs, how Fumei can be accepted by patients will also be a challenge.
Looking forward to the "quantity" and "quality" of innovative drugs
Chinese companies are vigorously promoting drug innovation. Previously, the report “Building a Sustainable Chinese Medicine Innovation Ecosystem†jointly issued by China Pharmaceutical Enterprise Management Association and China Chemical Pharmaceutical Industry Association pointed out that according to NatureIndex, China published in high-quality life science journals. The number of articles has increased from more than 4,000 in 2012 to more than 6,500 in 2015, second only to the United States, ahead of other traditional developed countries; the number of international patent applications for pharmaceuticals has risen from 756 in 2011 to 968 in 2015; The number of innovative drugs in the clinical phase increased from 21 in 2011 to 69 in 2015, and the number of compounds under study reached 656.
However, there is still a certain gap between the quality of China's already listed innovative drugs and the world's leading countries. At the end of 2015, there were 5,065 pharmaceutical production enterprises in China, which is the world's largest producer of APIs and preparations, but most of the products are generic drugs, and the homogenization is serious.
Zhu Xuejun, a tenured professor at Peking University, told reporters that the development of new drugs is a "gamble", and there are not many companies that can succeed in the end. "We claim that the original 6,000 pharmaceutical companies, now more than 5,000, are small and small, and secretly copied, which is low-cost. It has no strength, manpower, (some companies) and no funds to support the development of new drugs. Taking the 1.1 new drugs as an example, Zhu Xuejun said that the number of batches that can be approved each year is only a single digit.
In terms of innovative drug development, the reporter noted that the policy has given support. The relevant recommendations issued by the State Food and Drug Administration (CFDA) in February this year clearly stipulate that applications for registration of innovative drugs that are not marketed or sold in China or transferred to China will be given priority for review and approval.
According to industry insiders, the continuous optimization of the innovative drug system environment will help promote the production of innovative pharmaceutical companies and varieties. (Source: Daily Economic News original title: Red Birthmark New Drugs Will Be Listed in the Niche Market Can Support Medical Innovation)
Bluetooth TWS hearing earphones for impairment
Shenzhen Sunshine Technology Co.,Ltd , https://www.szyatwin.com